Chronic kidney disease (CKD) is defined by a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m
2, albuminuria of at least 30 mg per 24 hours, or markers of kidney damage (e.g., hematuria or structural abnormalities, such as polycystic or dysplastic kidneys) persisting for more than 3 months (
1). A permanent defect in the function or structure of the kidneys is known as end-stage renal disease (ESRD) and requires renal replacement therapies (
2). Hemodialysis is a treatment to filter wastes and fluid from the blood, as kidneys did, which is performed on fistula, graft, or catheter forms. Hemodialysis is performed in more than 90% of ESRD patients in the hospital setting (
3). Typically, hemodialysis is performed for 3 to 4 hours per week in each session (
4).
The incidence of ESRD is increasing substantially; it has increased 10-fold over a short period in the United States (
5,
6). Based on the published literature from Iran, the age-adjusted prevalence of CKD is 14.9% in Iran. It has become an important health problem associated with morbidity and mortality and decreased quality of life (
7). According to recent evidence, the annual incidence and prevalence of ESRD in Iran were 66 and 169 per million, respectively. Based on the epidemiologic evidence, about 54% of ESRD patients in Iran receive hemodialysis, and the rest undergo a kidney transplant (
8). The estimated cost of each hemodialysis session was about 74 US dollars, by which an annual cost of $1,1549 could be estimated for each patient (
9). Despite the high cost of treatment, these patients suffer from depression, stress, and familial and personal problems (
10).
In the United States, the 1-year and 5-year survival rates of peritoneal dialysis patients are 87% and 35%, respectively, and for hemodialysis patients, they are 79% and 34% (
11). In the limited studies in Iran, for example, in the north, the 1-year and 5-year survival rates of hemodialysis patients were 75% and 23%, respectively (
12). According to a study conducted in southern provinces, the 1- and 5-year survival rate of hemodialysis patients was 89.2% and 46.8%, respectively (
13). The survival rate of patients with vascular access type at hemodialysis was significantly higher than those with vascular access through graft (
14). Several factors contribute to high mortality in these patients, including age and sex. Moreover, patients with diabetes mellitus, polycystic kidney disease, hypertension, infections, glomerulonephritis, low body mass index (BMI), levels of serum cholesterol, homocysteine, creatinine, albumin, hemoglobin, history of stroke, dialysis adequacy, and renal replacement therapy had a greater risk of death (
15-
21). Among all the aforementioned factors, cardiovascular disease is the main cause of mortality in ESRD patients (
4).
Although there is growing evidence of hemodialysis patients' survival in developed countries, there is limited evidence in developing countries. Many researchers believe that there is substantial variability in mortality rates of dialysis patients across the world, which is possibly attributable to the variability in the population's background, genetics, and environmental factors (
22).